Bortezomib Regimen Yields Responses in B-Cell Marginal Zone Lymphoma

News
Article

A frontline treatment regimen including bortezomib and rituximab appears to be well tolerated among patients with B-cell non-Hodgkin marginal zone lymphoma in a phase 2 study.

“VR-CAP first-line treatment of lymphoma in the marginal region has a good effect…and well tolerated," according to the authors of a phase 2 study (NCT04433156).

“VR-CAP first-line treatment of lymphoma in the marginal region has a good effect…and well tolerated," according to the authors of a phase 2 study (NCT04433156).

Efficacy and tolerability were reported in patients with B-cell non-Hodgkin marginal zone lymphoma (MZL) treated with frontline bortezomib (Velcade), rituximab (Rituxan), cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride (VR-CAP), according to findings from a phase 2 study (NCT04433156) during the 2023 European Society for Medical Oncology Congress (ESMO).

Junfeng Chu, MD, and coauthors reported that the objective response rate in patients treated with VR-CAP was 95.5%. Additionally, toxicity mainly consisted of grade 1 and 2 adverse effects (AEs).

As of February 2023, 15 patients completed the cumulative 6 course treatment, 6 patients completed 4 courses of the total 6, and 2 discontinued the treatment of their own accord. In 22 patients, a curative effect could be evaluated. Among the 22 patients, 16 (72.7%) experienced either a complete response (CR) or unconfirmed complete response (CRu) and 5 patients (22.7%) experienced a partial response. After 2 years of treatment, the progression-free survival was 82.2% and the overall response was 82.0%, respectively.

“The primary end point was 2-year progression-free survival and the secondary end point was objective response rate, including complete response and partial response; total survival and security,” investigators wrote in the poster. “VR-CAP first-line treatment of lymphoma in the marginal region has a good effect…and well tolerated.”

The single arm, multi-center study evaluated 23 patients with a median age of 55 years (range, 25-74). Eighteen patients (78%) were under 60 years of age and 5 patients (22%) were 60 years or older. The male to female ratio was 14 to 9. Of the 23 patients, most (65%) had stage III or IV B-cell non-Hodgkin MZL (65%) and 35% of patients had stage I or II.

Eleven (47.8%) patients had a Follicular Lymphoma International Prognostic Index (FLIPI) of 0 to 1; 10 patients (43.5%) had a FLIPI score of 2 to 3, and 2 patients (8.7%) had a FLIPI score of 4. Turning to FLIPI-2 scores, 8 patients (34.8%) had a score of 0 to 1, 13 patients (56.5%) had a score of 2 to 2, and 2 patients (8.7%) had a score of 2.

Among the 23 patients, 2 patients (8.7%) experienced B symptoms while undergoing treatment compared with 21 patients (91.3%) who did not.

Patients receiving the full 6 treatment cycles showed a complete response (CR) of 66.7% and a partial response (PR) of 33.3%. Patients receiving four cycles of treatment had a CR of 33.3% and a PR of 57.1%. Additionally, patients who received 4 cycles of treatment reported 4.8% disease progression (PD) as well as 4.8% stable disease (SD). Among patients treated for 2 cycles, investigators reported a PR of 68.2%, a CR of 27.3%, and SD of 4.5%.

The first-line treatment comprised 6 cycles with each cycle lasting for 3 weeks. On the 0th day of the treatment cycle, a 375 mg/m2 dose of rituximab was given intravenously, as well as a 750 mg/m2 dose of cyclophosphamide, and a 70 mg/m2 dose of epirubicin (Ellence). On the first and fourth days, a 1.3 mg/m2 dose of bortezomib was given subcutaneously, and on the first and fifth day a 100 mg dose of prednisone was given orally.

The most common grade 1 or 2 AE experienced by 13 patients who completed the 6 courses of treatment were anemia (73.9%), gastrointestinal reaction (52.2%), thrombocytopenia (30.4%), pulmonary infection (21.7%, with 4.3% having grade 3 or 4), neurotoxicity (87%), and rituximab-related rash (8.7%).

For some patients with B-cell non-Hodgkin MZL, it can be difficult to achieve a complete remission with the standard treatment and many patients can relapse quickly. Thenuclear factor kappa B (NF-κB)signaling pathway is overly active. Bortezomib, works as a proteasome inhibitor interfering with the NF-κBpathway. This interference with the NF-κB pathway is one of the mechanisms through which bortezomib may exert its therapeutic effects in MZL.

The authors declared no conflict-of-interest disclosures.

Reference

Chu J, Wang H, Yao S, et al. Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma. Presented at: 2023 ESMO Congress. October 20 -24, 2023. Madrid, Spain. Abstract 834P.

Recent Videos
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides